StockNews.AI
ARVN
StockNews.AI
197 days

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

1. Arvinas will present Q4 and full year 2024 results on February 11, 2025. 2. The company develops therapies using its PROTAC protein degradation platform. 3. Arvinas is advancing multiple investigational drugs targeting serious diseases. 4. Upcoming results may influence market perceptions and investor sentiment significantly.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive financial results could enhance investor confidence, similar to prior quarters.

How important is it?

Earnings results directly impact stock valuation and investor outlook, affecting ARVN's market position.

Why Short Term?

Immediate reaction expected around the earnings announcement; long-term effects depend on clinical outcomes.

Related Companies

ARVNBCL6LRRK2ER+HER2-
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. Media:Kirsten Owens+1 (203) 584-0307Kirsten.Owens@arvinas.com

Related News